Related Experiment Video
Updated: Feb 17, 2026
09:16
Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
Published on: February 5, 2018
6.6K
Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis
Georg Greiner1, Michael Gurbisz1, Franz Ratzinger1
1Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Clinical Chemistry
|December 15, 2017
Summary
Digital PCR (dPCR) offers sensitive and precise detection of the KIT D816V mutation, crucial for diagnosing and prognosticating systemic mastocytosis (SM). This method outperforms traditional techniques, improving patient stratification and survival prediction in SM.
Area of Science:
- Hematology
- Molecular Diagnostics
- Oncology
Background:
- Accurate detection and quantification of KIT D816V are vital for diagnosing systemic mastocytosis (SM).
- Variant Allele Fraction (VAF) of KIT D816V predicts disease involvement and prognosis in advanced SM.
- Digital PCR (dPCR) shows promise for sensitive somatic mutation detection and quantification.
Purpose of the Study:
- To validate dPCR for KIT D816V detection and quantification.
- To compare dPCR performance against established methods like clamp-PCR and qPCR.
- To assess the clinical utility of dPCR-based KIT D816V VAF measurements in mastocytosis patients.
Main Methods:
- A validation study involving 302 peripheral blood and bone marrow samples from 156 mastocytosis patients.
- Comparison of dPCR with melting curve analysis after peptide nucleic acid-mediated PCR clamping (clamp-PCR).
- Comparison of dPCR with allele-specific quantitative real-time PCR (qPCR).
Main Results:
- dPCR demonstrated a limit of detection of 0.01% VAF with 8.5% CV, identifying KIT D816V in 90% of patients versus 70% for clamp-PCR (P < 0.001).
- dPCR showed high concordance with qPCR, confirming the clinical value of VAF measurements.
- Advanced SM patients had significantly higher KIT D816V VAF (median 2.43%) than indolent SM patients (median 0.14%; P < 0.001).
- dPCR confirmed the prognostic significance of high KIT D816V VAF for survival (P < 0.001).
Conclusions:
- dPCR for KIT D816V offers high precision and sensitivity, enabling interlaboratory standardization for allele burden measurement.
- dPCR is a suitable method for KIT D816V testing in mastocytosis patients.
- The findings support the clinical implementation of dPCR for improved mastocytosis management.
